Medtronic PLC reported its second-quarter earnings, revealing a revenue of $8.40 billion, which represents a year-over-year increase of 5.25% and exceeds expectations by $133 million. The company's earnings per share (EPS) for the quarter stood at $1.26, also beating estimates by $0.01. Despite surpassing quarterly expectations, Medtronic's stock experienced a decline, approaching sell zone territory, attributed to a supplier issue. In addition, the company raised its fiscal 2025 non-GAAP diluted EPS guidance to a range of $5.44 to $5.50, up from the previous range of $5.42 to $5.50. For the third quarter, Medtronic anticipates an EPS between $1.35 and $1.37, reflecting a positive outlook amid sustained demand for its medical devices in the United States.